Suppr超能文献

比较两种移植前预测模型和使用不同截断点的灵活 HCT-CI,以确定低、中、高危组:在接受 allo-RIC 的患者人群中,灵活 HCT-CI 是 NRM 和 OS 的最佳预测因子。

Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.

机构信息

Hematology and Stem Cell Transplantation Division Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain.

出版信息

Biol Blood Marrow Transplant. 2010 Mar;16(3):413-20. doi: 10.1016/j.bbmt.2009.11.008. Epub 2009 Nov 14.

Abstract

Patient comorbidities are being increasingly analyzed as predictors for outcome after hematopoietic stem cell transplantation (HSCT), especially in allogeneic HSCT (Allo-HSCT). Researchers from Seattle have recently developed several pretransplant scoring systems (hematopoietic cell transplantation comorbidity index [HCT-CI] and the Pretransplantation Assessment of Mortality (PAM) model) from large sets of HSCT recipients with the aim of improving non-transplant models, mainly the Charlson Comorbidity Index (CCI). The validation of these comorbidity indexes in other institutions and in different disease and conditioning-related settings is of interest to determine whether these models are potentially applicable in clinical practice and in research settings. We performed a retrospective study in our institution including 194 consecutive reduced-intensity conditioning (RIC) AlloHSCT (allo-RIC) recipients to compare the predictive value of the PAM score, CCI, the original HCT-CI, and the flexible HCT-CI using a different risk group stratification. The median patient pretransplant scores for the HCT-CI, PAM, and CCI were 3.5, 22, and 0, respectively. The flexible HCT-CI risk-scoring system (restratified as: low risk [LR] 0-3 points, intermediate risk [IR] 4-5 points, and high risk [HR] >5 points) was the best predictor for non-relapse mortality (NRM). The 100-day and 2-year NRM incidence in these risk categories was 4% (95% confidence interval C.I. 2%-11%), 16% (95% C.I. 9%-31%), and 29% (95% C.I. 19%-45%), respectively (P < .001), and 19% (95% C.I. 12%-28%), 33% (95% C.I. 22%-49%), and 40% (95% C.I. 28%-56%), respectively (P=.01). However, we found no predictive value for NRM using neither the original HCT-CI nor the PAM or CCI models. The better predictive capacity for NRM of the flexible HCT-CI than PAM and CCI was confirmed with the c-statistics (c-statistics of 0.672, 0.634, and 0.595, respectively). Regarding the 2-year overall survival (OS), the flexible HCT-CI score categories were also associated with the highest predictive HR. In conclusion, our single-center study suggests that the flexible HCT-CI is a good predictor of 2-year NRM and survival after an allo-RIC.

摘要

患者合并症越来越多地被分析为造血干细胞移植(HSCT)后结局的预测因素,尤其是异基因 HSCT(Allo-HSCT)。来自西雅图的研究人员最近从大量 HSCT 受者中开发了几种移植前评分系统(造血细胞移植合并症指数[HCT-CI]和移植前死亡率评估[PAM]模型),旨在改进非移植模型,主要是 Charlson 合并症指数(CCI)。这些合并症指数在其他机构和不同疾病及预处理相关环境中的验证对于确定这些模型是否可能在临床实践和研究环境中应用具有重要意义。我们在本机构进行了一项回顾性研究,纳入了 194 例连续接受低强度预处理(RIC)allo-HSCT(allo-RIC)的患者,以比较 PAM 评分、CCI、原始 HCT-CI 和使用不同风险分组分层的灵活 HCT-CI 的预测价值。HCT-CI、PAM 和 CCI 的中位患者移植前评分分别为 3.5、22 和 0。灵活的 HCT-CI 风险评分系统(重新分层为:低危[LR]0-3 分,中危[IR]4-5 分,高危[HR]>5 分)是非复发死亡率(NRM)的最佳预测因素。在这些风险类别中,100 天和 2 年 NRM 发生率分别为 4%(95%置信区间[CI]2%-11%)、16%(95%CI 9%-31%)和 29%(95%CI 19%-45%)(P<.001),19%(95%CI 12%-28%)、33%(95%CI 22%-49%)和 40%(95%CI 28%-56%)(P=.01)。然而,我们发现原始 HCT-CI 或 PAM 或 CCI 模型对 NRM 均无预测价值。与 PAM 和 CCI 相比,灵活的 HCT-CI 对 NRM 的预测能力更强,其 C 统计量分别为 0.672、0.634 和 0.595。关于 2 年总生存率(OS),灵活的 HCT-CI 评分类别也与最高预测 HR 相关。总之,我们的单中心研究表明,灵活的 HCT-CI 是 allo-RIC 后 2 年 NRM 和生存的良好预测因子。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验